← board
PRE
distress 0/10 · well-funded / low risk$20.56-6%today-7% from 52w high
Revenue
$36M
Liquidity
$108M
Runway
5.0 yrs
Shares 1y
0%
Price & events
+8.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.9%
1D
+8.7%
1W
+3.2%
1M
+17.5%
3M
+11.6%
6M
+138.2%
1Y
+267.1%
2Y
-81.8%
5Y
-82.4%
All
Overview
- Market Cap
- $346.93M
- Volume
- 37.46K
- 52 Week Range
- $7.25 – $22.15
- Total Shares
- 16.87M
- Float Shares
- 12.63M
- Short %
- 3.84%
- % Held by Insiders
- 14.16%
- % Held by Institutions
- 12.84%
- RVOL
- 0.16x
- Beta
- 0.25
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-10earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 16,874,089 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $34 (+66% upside) · 5 analysts
- 2026-07-15BenchmarkBuy
- 2026-06-16BenchmarkBuy
- 2026-03-16Lake StreetBuy
- 2025-10-29Cantor FitzgeraldOverweight
- 2025-01-16Cantor FitzgeraldOverweight
- 2024-12-04Cantor FitzgeraldOverweight
Competitors
- none identified
Recent news
- 2026-07-15PRE Maintains Buy Rating by Benchmark -- Price Target Raised to $40 - GuruFocus
- 2026-07-15David Beckham’s Prenetics Secures $1B From General Catalyst to Scale IM8 Wellness Brand - citybiz
- 2026-07-14Prenetics (PRE) Secures $1B Growth Financing for IM8 Initiatives - GuruFocus
- 2026-07-14Prenetics (NASDAQ: PRE) lifts IM8 outlook after $1B General Catalyst financing - Stock Titan
- 2026-07-07Prenetics Global (PRE) director receives 2,000 shares from vested RSUs - Stock Titan
- 2026-03-24Pay $49, test 100+ biomarkers: Prenetics ties supplements to proof - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.